KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Moderna (MRNA) Gross Margin (2020 - 2025)

Historic Gross Margin for Moderna (MRNA) over the last 6 years, with Q3 2025 value amounting to 79.63%.

  • Moderna's Gross Margin rose 72300.0% to 79.63% in Q3 2025 from the same period last year, while for Sep 2025 it was 48.25%, marking a year-over-year decrease of 187700.0%. This contributed to the annual value of 54.76% for FY2024, which is 232900.0% up from last year.
  • Latest data reveals that Moderna reported Gross Margin of 79.63% as of Q3 2025, which was up 72300.0% from 16.2% recorded in Q2 2025.
  • In the past 5 years, Moderna's Gross Margin registered a high of 90.04% during Q1 2021, and its lowest value of 112.5% during Q2 2023.
  • In the last 5 years, Moderna's Gross Margin had a median value of 66.95% in 2023 and averaged 47.57%.
  • Its Gross Margin has fluctuated over the past 5 years, first plummeted by -1834200bps in 2023, then soared by 1471600bps in 2024.
  • Moderna's Gross Margin (Quarter) stood at 86.8% in 2021, then fell by -28bps to 62.27% in 2022, then grew by 8bps to 66.95% in 2023, then tumbled by -65bps to 23.5% in 2024, then surged by 239bps to 79.63% in 2025.
  • Its Gross Margin was 79.63% in Q3 2025, compared to 16.2% in Q2 2025 and 16.67% in Q1 2025.